Karimian Pegah, Hovsepian Silva, Alinia Tahereh, Raispour Homeyra, Mirshahzadeh Naghmeh, Hashemipour Mahin
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Department of Pediatric Endocrinology, School of Medicine, Iran University of Medical Sciences, Ali Asghar Children's Hospital, Tehran, Iran
Ann Pediatr Endocrinol Metab. 2024 Dec;29(6):371-378. doi: 10.6065/apem.2448014.007. Epub 2024 Dec 31.
We compared the age at menarche and standard deviation score (SDS) of final height (FH) in permanent congenital hypothyroidism (CH) patients with those of healthy female adolescents and assessed their associations with CH screening-related variables or demographic factors.
In this cross-sectional study, we included 207 female CH patients and 598 healthy age-matched female adolescents. Ages at puberty onset and menarche, height at puberty and menarche, and the FH and its SDS were evaluated in the 2 groups and compared. Associations between screening variables and anthropometric data with age at menarche and SDS of FH were also assessed in CH patients.
In the included population, 113 patients with CH and 453 healthy girls attained their FH. The mean ages at puberty onset and menarche in CH patients were higher than those in the healthy population (P<0.05). The mean height at menarche and the FH and its SDS were not different between the 2 groups (P>0.05). There was no significant association between FH SDS in CH patients and age of treatment (P=0.30). Age at menarche was significantly higher in CH patients with delayed age at treatment initiation (P=0.04). The difference between FH and target height was not significantly different among CH patients (P=0.83).
While CH patients had a significantly higher age at menarche compared to the healthy population, appropriate treatment changed this age to be similar to that in the healthy group. However, CH patients who experienced delayed treatment had a higher age at menarche. Age at treatment initiation was the only screening-related variable related to age at onset of menarche and puberty.
我们比较了永久性先天性甲状腺功能减退症（CH）患者的初潮年龄和最终身高（FH）的标准差评分（SDS）与健康女性青少年的情况，并评估了它们与CH筛查相关变量或人口统计学因素的关联。
在这项横断面研究中，我们纳入了207名女性CH患者和598名年龄匹配的健康女性青少年。评估并比较了两组的青春期开始和初潮年龄、青春期和初潮时的身高、FH及其SDS。还评估了CH患者中筛查变量和人体测量数据与初潮年龄和FH的SDS之间的关联。
在所纳入的人群中，113例CH患者和453名健康女孩达到了她们的FH。CH患者青春期开始和初潮的平均年龄高于健康人群（P<0.05）。两组初潮时的平均身高、FH及其SDS没有差异（P>0.05）。CH患者的FH SDS与治疗年龄之间没有显著关联（P=0.30）。治疗开始年龄延迟的CH患者初潮年龄显著更高（P=0.04）。CH患者中FH与目标身高之间的差异没有显著差异（P=0.83）。
虽然CH患者的初潮年龄显著高于健康人群，但适当的治疗使这个年龄与健康组相似。然而，治疗延迟的CH患者初潮年龄更高。治疗开始年龄是与初潮和青春期开始年龄相关的唯一筛查相关变量。
